264 related articles for article (PubMed ID: 29389745)
1. Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center.
Alldredge B; Jordan A; Imitola J; Racke MK
Clin Neuropharmacol; 2018; 41(2):56-59. PubMed ID: 29389745
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience.
D'Amico E; Zanghì A; Chisari CG; Fermo SL; Toscano S; Arena S; Patti F; Zappia M
Mult Scler Relat Disord; 2019 Jan; 27():324-326. PubMed ID: 30471585
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
[TBL] [Abstract][Full Text] [Related]
4. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
Rommer PS; Dörner T; Freivogel K; Haas J; Kieseier BC; Kümpfel T; Paul F; Proft F; Schulze-Koops H; Schmidt E; Wiendl H; Ziemann U; Zettl UK;
J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235
[TBL] [Abstract][Full Text] [Related]
5. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the efficacy and safety of Zytux
Naser Moghadasi A; Darki A; Masoumi P; Hashemi SN; Ghadiri F
Mult Scler Relat Disord; 2019 Nov; 36():101419. PubMed ID: 31586800
[TBL] [Abstract][Full Text] [Related]
7. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis.
Uzawa A; Mori M; Hayakawa S; Masuda S; Kuwabara S
Eur J Neurol; 2010 May; 17(5):672-6. PubMed ID: 20039942
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
Annovazzi P; Capobianco M; Moiola L; Patti F; Frau J; Uccelli A; Centonze D; Perini P; Tortorella C; Prosperini L; Lus G; Fuiani A; Falcini M; Martinelli V; Comi G; Ghezzi A
J Neurol; 2016 Sep; 263(9):1727-35. PubMed ID: 27286847
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of rituximab in refractory neuromyelitis optica.
Collongues N; Brassat D; Maillart E; Labauge P; Ouallet JC; Carra-Dalliere C; Moreau T; Bourre B; Papeix C; Brochet B; Audoin B; Vukusic S; de Seze J; Marignier R;
Mult Scler; 2016 Jun; 22(7):955-9. PubMed ID: 26362900
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study.
Zhao D; Zhao C; Lu J; Han Y; Sun T; Ren K; Ma C; Zhang C; Li H; Guo J
Mult Scler Relat Disord; 2023 Feb; 70():104518. PubMed ID: 36657326
[TBL] [Abstract][Full Text] [Related]
11. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.
Gao F; Chai B; Gu C; Wu R; Dong T; Yao Y; Zhang Y
BMC Neurol; 2019 Mar; 19(1):36. PubMed ID: 30841862
[TBL] [Abstract][Full Text] [Related]
13. Early relapse after RTX initiation in a patient with NMO/MS overlap syndrome: How long to conclude to a failure treatment?
Maillart E; Lippi A; Lubetzki C; Louapre C; Papeix C
Mult Scler Relat Disord; 2018 Feb; 20():220-222. PubMed ID: 29433095
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in multiple sclerosis at general hospital level.
Hellgren J; Risedal A; Källén K
Acta Neurol Scand; 2020 Jun; 141(6):491-499. PubMed ID: 31990978
[TBL] [Abstract][Full Text] [Related]
15. Impact of rituximab in Mexican patients with Multiple Sclerosis-A single-center retrospective study.
Bribiesca-Contreras E; García-Estrada C; Gómez-Figueroa E; Zertuche-Ortuño L; Rodríguez-Rivas R; Marcín-Sierra M; Delgado-Niño M; Rivas-Alonso V; Corona-Vázquez T; Flores-Rivera J
Mult Scler Relat Disord; 2022 Feb; 58():103485. PubMed ID: 35042092
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of rituximab treatment for neuromyelitis optica.
Fernández-Megía MJ; Casanova-Estruch B; Pérez-Miralles F; Ruiz-Ramos J; Alcalá-Vicente C; Poveda-Andrés JL
Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
[TBL] [Abstract][Full Text] [Related]
17. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
[TBL] [Abstract][Full Text] [Related]
18. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
Castillo-Trivino T; Braithwaite D; Bacchetti P; Waubant E
PLoS One; 2013; 8(7):e66308. PubMed ID: 23843952
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.
Scotti B; Disanto G; Sacco R; Guigli M; Zecca C; Gobbi C
PLoS One; 2018; 13(5):e0197415. PubMed ID: 29758075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]